Choose language
< Return to main menu

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

WuXi STA

Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi Chemistry

End-to-End CRDMO Platform for Synthetic Molecules

WuXi STA

Integrated CMC Platform from Preclinical to Commercial

About Us

WuXi Chemistry, a business division of WuXi AppTec, provides contract services for new drug development from discovery to commercial.  Our unique CRDMO model offers an integrated solution combining traditional CRO (contract research organization), CDMO (contract development and manufacturing organization) and CMO (contract manufacturing organization) services under one roof.

As a world leading chemistry service organization, WuXi Chemistry have over 18,000 employees from our 15 research, development or manufacturing sites worldwide, serving over 1,800 clients from top pharma to virtual biotech companies.  Our services cover all categories for all synthetic molecular modalities, meeting any material requirement at any scale.

WuXi Chemisty CRDMO Capability

CRO

CDMO

CMO

Target to Hit

Hit to Lead

Lead to PCC

Preclinical

Platform

Phase II

Phase III

Commercial Manufacturing

Capable at Any Scale

Milligram

Gram

10-100G

Kilogram

10-100KG

Metric Ton

Cover All Categories for All Synthetic Molecular Modalities

Non-GMP

GMP

API

Drug Product

Small Molecule

Oligonucleotide

Peptide

Conjugate

HPAPI